Awakn’s Dr. Ben Sessa: Ketamine Assisted Therapy Providing “Breakthrough, Transformative Experience” Jan 31, 2023
Numinus Announces Strong Appointment Growth As Studies Demonstrate Ketamine Effectiveness For Depression Sep 20, 2022
Awakn Life Sciences Receives UK State Funding to Identify Optimal Pathway to Market in UK & US for Its Lead… Jul 5, 2022
Awakn Life Sciences: Key Patent Filed Covering Behavioral Addictions With Ketamine And Ketamine-Assisted Therapy May 27, 2022
Awakn Life Sciences Files Patent Cooperation Treaty (PCT) Application For The Treatment Of Behavioral Addictions May 26, 2022
Awakn Life Sciences Completes The World’s First Ketamine Treatment Study For Behavioral Addictions May 20, 2022
Awakn Life Sciences Completes World’s First Ketamine Treatment Study for a Range of Behavioral Addictions May 19, 2022
